Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia

April 4, 2019 updated by: Jun Soo Kwon, Seoul National University Hospital
The purpose of this study is to evaluate abnormal dopamine synthesis and connectivity according to the antipsychotic treatment response in schizophrenia.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

36

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 55 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

  1. Schizophrenia patients treated with clozapine
  2. Schizophrenia patients treated with risperidone or paliperidone or olanzapine
  3. Healthy volunteers

Description

Inclusion Criteria:

  • diagnosis of schizophrenia
  • clinically stable state

Exclusion Criteria:

  • history of previous head injury, epileptic disorder, other medical comorbidity
  • substance abuse/dependence

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Clozapine
stable patients treated with clozapine
Other: patients treated with antipsychotics
Other antipsychotics
stable patients treated with risperidone or paliperidone or olanzapine
Other: patients treated with antipsychotics
Healthy volunteer
healthy controls
Other: patients treated with antipsychotics

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Striatal [18F]-DOPA uptake measured using positron emission tomographic 18F-dopa imaging.
Time Frame: within 2 weeks from enrollment
within 2 weeks from enrollment

Secondary Outcome Measures

Outcome Measure
Time Frame
resting state functional magnetic resonance imaging
Time Frame: within 2 weeks from enrollment
within 2 weeks from enrollment
diffusion tensor imaging
Time Frame: within 2 weeks from enrollment
within 2 weeks from enrollment
clinical measure including Positive and Negative Syndrome Scale
Time Frame: within 2 weeks from enrollment
within 2 weeks from enrollment
neurocognitive function test
Time Frame: within 2 weeks from enrollment
within 2 weeks from enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seoul National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2014

Primary Completion (Actual)

May 1, 2016

Study Completion (Actual)

May 1, 2016

Study Registration Dates

First Submitted

September 22, 2014

First Submitted That Met QC Criteria

September 22, 2014

First Posted (Estimate)

September 25, 2014

Study Record Updates

Last Update Posted (Actual)

April 8, 2019

Last Update Submitted That Met QC Criteria

April 4, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 3420130030

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Schizophrenia

Clinical Trials on patients treated with antipsychotics

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe